The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.

Kaiser Permanente contributed to a round that pushed the total raised by the ceullar cancer therapy developer to $300m.

Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.

The healthcare data integrator boosted its overall funding to $53m in a series B round led by Blue Venture Fund that included Echo Health Ventures.

TU Delft and Imperial-founded genetic data analytics software provider BlueBee has been picked up after raising at least $13.5m of funding.

Grand Decade and existing investor Boehringer Ingelheim Venture Fund helped supply $38.2m for the mRNA immunotherapy developer and Vrije Universiteit Brussel spinout.

Uniseed has entered a co-investment pact with BioCurate, a drug discovery fund for early-stage University of Melbourne and Monash University research.

Founded by University of Washington faculty, Proprio has raised series A funding to commercialise its multi-camera surgical imaging system.

Backed by Intel and HTC as of its launch early last year, Proprio has now raised a total of $30m to commercialise its multi-camera surgical imaging system.

Grand Decade and existing investor Boehringer Ingelheim Venture Fund helped supply $38.2m for the mRNA immunotherapy developer and Vrije Universiteit Brussel spinout.